345 completed. 345 Phase 3, 34 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 345 | Completed 345 |
| Phase 2 | 34 | Completed 34 |
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia KarXT - Schizophrenia | Phase 3 | Completed | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 173 | 2024-10-28 | 2026-06-22 |
| An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia Study App - Schizophrenia, Negative Symptoms in Schizophrenia | Phase 3 | Completed | Click Therapeutics, Inc. | 73 | 2023-09-12 | 2026-06-05 |
| A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia Xanomeline and Trospium Chloride Capsules, Placebo - Schizophrenia | Phase 3 | Completed | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 202 | 2023-05-29 | 2025-12-17 |
| Metformin Treatment on Cognitive Impairment of Schizophrenia Metformin treatment, Placebo treatment, Baseline assessments - Schizophrenia | Phase 3 | Completed | Central South University | 120 | 2023-05-08 | 2026-07-31 |
| Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005 LYN-005, Risperidone - Schizophrenia, Schizoaffective Disorder | Phase 3 | Completed | Lyndra Inc. | 83 | 2023-04-13 | 2024-10-24 |
| An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication SEP-363856 - Schizophrenia | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 75 | 2023-03-31 | 2025-12-11 |
| Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia CT-155, Digital Control - Schizophrenia | Phase 3 | Completed | Click Therapeutics, Inc. | 464 | 2023-03-31 | 2026-06-12 |
| A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia TV-44749, Placebo - Schizophrenia | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D LLC | 675 | 2023-01-24 | 2026-03-17 |
| A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication SEP-363856 - Schizophrenia | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 101 | 2022-12-19 | 2025-12-11 |
| Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) BXCL501, Matching Placebo - Agitation,Psychomotor, Bipolar I Disorder | Phase 3 | Completed | BioXcel Therapeutics Inc | 452 | 2022-11-21 | 2026-08-07 |
| A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia OPC-34712FUM/ Brexpiprazole fumarate - Schizophrenia | Phase 3 | Completed | Otsuka Pharmaceutical Co., Ltd. | 247 | 2022-05-31 | 2026-09-11 |
| An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia Xanomeline and Trospium Chloride Capsules - Schizophrenia | Phase 3 | Completed | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 290 | 2022-03-07 | 2026-07-31 |
| Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia Placebo, Valbenazine - Schizophrenia | Phase 3 | Completed | Neurocrine Biosciences | 442 | 2021-11-29 | 2026-02-10 |
| A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia Xanomeline and Trospium Chloride Capsules, Placebo - Schizophrenia | Phase 3 | Completed | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 396 | 2021-11-12 | 2026-05-05 |
| Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1) Iclepertin, Placebo - Schizophrenia | Phase 3 | Completed | Boehringer Ingelheim | 620 | 2021-09-08 | 2025-11-05 |
| Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2) Iclepertin, Placebo - Schizophrenia | Phase 3 | Completed | Boehringer Ingelheim | 611 | 2021-08-24 | 2025-12-12 |
| CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia Iclepertin, Placebo - Schizophrenia | Phase 3 | Completed | Boehringer Ingelheim | 609 | 2021-08-09 | 2026-02-06 |
| Lumateperone for the Prevention of Relapse in Patients With Schizophrenia Lumateperone 42 mg, Placebo - Schizophrenia | Phase 3 | Completed | Intra-Cellular Therapies, Inc. | 592 | 2021-07-08 | 2026-10-05 |
| Memantine Augmentation of Targeted Cognitive Training in Schizophrenia Memantine, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 2 / Phase 3 | Completed | University of California, San Diego | 62 | 2021-07-06 | 2026-05-18 |
| An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) Xanomeline and Trospium Chloride Capsules - Schizophrenia | Phase 3 | Completed | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 566 | 2021-06-02 | 2025-09-17 |
Showing 20 of 345. Sign in to see all of them.
Psychotic Disorders (78) · Mental Disorders (21) · Bipolar Disorder (11) · Psychomotor Agitation (6) · Cognition Disorders (4) · Depressive Disorder, Major (4) · Cognitive Dysfunction (3) · Depression (3) · Disease (3) · Hallucinations (3) · Metabolic Syndrome (3) · Anxiety Disorders (2) · Disorders of Sex Development (2) · Mania (2)
Schizophrenia Spectrum and Other Psychotic Disorders (344) · Mental Disorders (324) · Pathological Conditions, Signs and Symptoms (21) · Behavior (20) · Signs and Symptoms (17) · Nervous System Diseases (14) · Neurologic Manifestations (14) · Mood Disorders (13) · Neurobehavioral Manifestations (12) · Bipolar and Related Disorders (11) · Behavioral Symptoms (10) · Dyskinesias (7) · Neurocognitive Disorders (7) · Aberrant Motor Behavior in Dementia (6) · Psychomotor Disorders (6)
Risperidone (50) · Olanzapine (37) · Paliperidone Palmitate (36) · Aripiprazole (35) · Quetiapine Fumarate (21) · asenapine (19) · Lurasidone Hydrochloride (18) · ziprasidone (12) · brexpiprazole (10) · Haloperidol (7) · trospium chloride (7) · xanomeline (7) · SEP-363856 (5) · bifeprunox (5) · sertindole (5)
Otsuka Pharmaceutical Development & Commercialization, Inc. (33) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (32) · Organon and Co (18) · AstraZeneca (16) · Sumitomo Pharma America, Inc. (13) · H. Lundbeck A/S (12) · Alkermes, Inc. (10) · Eli Lilly and Company (10) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (9) · Janssen Research & Development, LLC (8) · Karuna Therapeutics, Inc., a Bristol Myers Squibb company (8) · Hoffmann-La Roche (6) · Janssen, LP (6) · Janssen-Cilag International NV (6) · Forest Laboratories (5)
United States (158) · Russia (61) · Ukraine (53) · Romania (46) · Bulgaria (39) · Poland (38) · South Korea (35) · France (32) · Japan (31) · Serbia (31) · Spain (31) · Taiwan (31) · India (28) · China (27) · Canada (25)
PMID 20537128, PMID 20537130, PMID 22198451, PMID 24423017, PMID 28433500, PMID 33854317, PMID 34091867, PMID 18466043, PMID 21155708, PMID 22935168, PMID 24955752, PMID 27816567, PMID 28117049, PMID 28640988, PMID 32606705, PMID 34751928, PMID 34901863, PMID 35235720, PMID 39144777, PMID 41233083, PMID 42474330, PMID 19210948, PMID 23290326, PMID 24035633, PMID 24754314, PMID 25367164, PMID 25711509, PMID 26091193, PMID 26117157, PMID 27743205, PMID 28350572, PMID 28478771, PMID 30470662, PMID 30994855, PMID 32841554, PMID 33761928, PMID 34894307, PMID 36115192, PMID 36883881, PMID 37480362, PMID 37756123, PMID 39145678, PMID 40047530, PMID 40212458, PMID 40215379, PMID 40730715, PMID 41272239, PMID 41944743, PMID 42138587, PMID 42623271
2019 (4), 2015 (3), 2004 (2), 2009 (2), 2017 (2), 2018 (2), 2005 (1), 2008 (1), 2014 (1), 2016 (1), P50MH103222 (1), R01DA022495 (1), R01MH050787 (1), R01MH059807 (1), R01MH060902 (1)